Melanoma/Skin Cancer News

Tissue-rearranging reconstruction is needed more in melanomas of the head and neck, which have high local recurrence rates, compared with keratinocyte carcinomas, according to a study.

The combination of pembrolizumab and low-dose ipilimumab appeared tolerable and led to significant antitumor activity among patients with advanced melanoma who previously failed prior immunotherapy, according to phase 2 study results.

Experts continued to see a decrease in overall cancer mortality among men and women of all races and ethnicities in the United States toward the end of the last decade, according to the Annual Report to the Nation on the Status of Cancer.

Metformin, even in low doses, may be associated with a decreased risk for basal cell carcinoma, according to a study.

Moffitt Cancer Center in Tampa has been one of the early leaders in cellular therapies for cancer treatment.

The FDA expanded the approval of pembrolizumab to include treatment of patients with locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, according to the agent’s manufacturer.

Chlormethine gel showed efficacy in combination with corticosteroids or other treatments such as phototherapy in a cohort of patients with mycosis fungoides cutaneous T-cell lymphoma, according to the PROVe study.

A blood-based test demonstrated efficacy and high specificity in detecting multiple cancer types with diverse biological features, paving the way for a new screening option, according to research published in Annals of Oncology.

Each 6-month decrease in exposure to immune checkpoint inhibitors nearly doubled the duration of response to therapy with lifileucel among patients with metastatic melanoma, according to long-term results of a phase 2 study.

Patients with cancer and overweight or obesity had better outcomes with immune checkpoint inhibitors than lighter patients, but only when they received weight-based dosing of the therapy, study results showed.